CN1197391A - 应用(2－咪唑啉－2－基氨基)喹喔啉治疗视神经损伤的方法 - Google Patents

应用(2－咪唑啉－2－基氨基)喹喔啉治疗视神经损伤的方法 Download PDF

Info

Publication number
CN1197391A
CN1197391A CN96196328A CN96196328A CN1197391A CN 1197391 A CN1197391 A CN 1197391A CN 96196328 A CN96196328 A CN 96196328A CN 96196328 A CN96196328 A CN 96196328A CN 1197391 A CN1197391 A CN 1197391A
Authority
CN
China
Prior art keywords
compound
formula
deleterious effect
glaucoma
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN96196328A
Other languages
English (en)
Chinese (zh)
Inventor
L·A·维勒
E·沃德穆塞
R·K·黎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
A Legen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23971914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1197391(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A Legen filed Critical A Legen
Publication of CN1197391A publication Critical patent/CN1197391A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN96196328A 1995-06-28 1996-06-17 应用(2－咪唑啉－2－基氨基)喹喔啉治疗视神经损伤的方法 Pending CN1197391A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/496,262 1995-06-28
US08/496,262 US5856329A (en) 1995-06-28 1995-06-28 Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN2006101011051A Division CN1943577B (zh) 1995-06-28 1996-06-17 (2-咪唑啉-2-基氨基)喹喔啉在制备用于治疗视神经损伤的药物中的应用
CN200910178530A Division CN101683343A (zh) 1995-06-28 1996-06-17 (2-咪唑啉-2-基氨基)喹喔啉的制药应用

Publications (1)

Publication Number Publication Date
CN1197391A true CN1197391A (zh) 1998-10-28

Family

ID=23971914

Family Applications (3)

Application Number Title Priority Date Filing Date
CN96196328A Pending CN1197391A (zh) 1995-06-28 1996-06-17 应用(2－咪唑啉－2－基氨基)喹喔啉治疗视神经损伤的方法
CN200910178530A Pending CN101683343A (zh) 1995-06-28 1996-06-17 (2-咪唑啉-2-基氨基)喹喔啉的制药应用
CN2006101011051A Expired - Lifetime CN1943577B (zh) 1995-06-28 1996-06-17 (2-咪唑啉-2-基氨基)喹喔啉在制备用于治疗视神经损伤的药物中的应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN200910178530A Pending CN101683343A (zh) 1995-06-28 1996-06-17 (2-咪唑啉-2-基氨基)喹喔啉的制药应用
CN2006101011051A Expired - Lifetime CN1943577B (zh) 1995-06-28 1996-06-17 (2-咪唑啉-2-基氨基)喹喔啉在制备用于治疗视神经损伤的药物中的应用

Country Status (14)

Country Link
US (1) US5856329A (enExample)
EP (3) EP1611891B1 (enExample)
JP (3) JP4621306B2 (enExample)
KR (1) KR19990028403A (enExample)
CN (3) CN1197391A (enExample)
AT (2) ATE322267T1 (enExample)
AU (1) AU715742B2 (enExample)
BR (1) BR9609219A (enExample)
CA (1) CA2225626C (enExample)
DE (2) DE69636012T3 (enExample)
DK (1) DK0835110T4 (enExample)
ES (2) ES2333339T3 (enExample)
PT (1) PT835110E (enExample)
WO (1) WO1997001339A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100569291C (zh) * 2000-07-14 2009-12-16 阿勒根公司 含有α-2肾上腺素能激动剂的组合物
CN1964627B (zh) * 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
WO1999025350A1 (en) * 1997-11-14 1999-05-27 Alcon Laboratories, Inc. Treatment of diabetic retinopathy
WO2004073708A1 (en) 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US6247473B1 (en) 1999-02-18 2001-06-19 Third Millenium Trust System and method for testing the neuroprotective or neuroregenerative effects of drugs
JP2003514015A (ja) * 1999-11-12 2003-04-15 アルコン，インコーポレイテッド 眼の状態を処置するためのニューロフィリンリガンド
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
DE10013318A1 (de) * 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
DE10035620B4 (de) * 2000-07-21 2005-07-14 *Acri.Tec Gesellschaft für ophthalmologische Produkte mbH Verwendung von Taurin als neuroprotektives Agens in der Ophthalmologie
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US7534795B2 (en) * 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
CA2641501A1 (en) * 2006-02-06 2007-08-16 Nicox S.A. Nitrooxy-comprising derivatives of apraclonidine and brimodnidine as al pha2 -adrenergic receptor agonists
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2009023752A1 (en) * 2007-08-15 2009-02-19 Allergan, Inc. Adrenergic compounds
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
NZ628266A (en) 2009-11-09 2016-02-26 Allergan Inc Compositions and methods for stimulating hair growth
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
JP6511401B2 (ja) 2013-02-15 2019-05-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続型薬物送達インプラント
WO2015129809A1 (ja) * 2014-02-28 2015-09-03 国立大学法人京都大学 虚血性眼疾患の処置用の医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4587257A (en) * 1984-12-14 1986-05-06 Alcon Laboratories, Inc. Control of ocular bleeding using clonidine derivatives
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5021410A (en) * 1989-05-22 1991-06-04 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
CN1137755A (zh) † 1993-12-17 1996-12-11 普罗克特和甘保尔公司 用作α-2肾上腺素能受体兴奋剂的6-(2-咪唑啉基氨基)喹喔啉化合物
WO1996013267A2 (en) * 1994-10-27 1996-05-09 Allergan Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100569291C (zh) * 2000-07-14 2009-12-16 阿勒根公司 含有α-2肾上腺素能激动剂的组合物
CN101897704B (zh) * 2000-07-14 2014-10-29 阿勒根公司 含有α-2肾上腺素能激动剂的组合物
CN1964627B (zh) * 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物

Also Published As

Publication number Publication date
CA2225626A1 (en) 1997-01-16
ES2333339T3 (es) 2010-02-19
JP2001503370A (ja) 2001-03-13
DE69638072D1 (de) 2009-12-24
WO1997001339A1 (en) 1997-01-16
JP2011042668A (ja) 2011-03-03
ATE322267T1 (de) 2006-04-15
CN1943577A (zh) 2007-04-11
EP1642581A3 (en) 2006-12-27
ATE447956T1 (de) 2009-11-15
ES2262157T5 (es) 2011-11-10
EP0835110B1 (en) 2006-04-05
DK0835110T3 (da) 2006-08-14
PT835110E (pt) 2006-08-31
MX9710480A (es) 1998-08-30
DE69636012D1 (de) 2006-05-18
EP1611891B1 (en) 2012-08-22
AU715742B2 (en) 2000-02-10
EP1642581B1 (en) 2009-11-11
ES2262157T3 (es) 2006-11-16
DK0835110T4 (da) 2011-09-12
CN1943577B (zh) 2013-06-12
EP1611891A3 (en) 2007-03-14
BR9609219A (pt) 1999-02-17
DE69636012T3 (de) 2012-01-05
EP1611891A2 (en) 2006-01-04
KR19990028403A (ko) 1999-04-15
CA2225626C (en) 2002-09-03
JP4621306B2 (ja) 2011-01-26
EP1642581A2 (en) 2006-04-05
DE69636012T2 (de) 2006-11-09
US5856329A (en) 1999-01-05
CN101683343A (zh) 2010-03-31
JP2006241138A (ja) 2006-09-14
EP0835110B2 (en) 2011-06-15
AU6386496A (en) 1997-01-30
EP0835110A1 (en) 1998-04-15

Similar Documents

Publication Publication Date Title
CN1943577B (zh) (2-咪唑啉-2-基氨基)喹喔啉在制备用于治疗视神经损伤的药物中的应用
US6465464B2 (en) Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
Kramer Epinephrine distribution after topical administration to phakic and aphakic eyes
WO1993014757A1 (en) Treatment of low pressure glaucoma and ischemic retinal degeneration with droperidol
US5252568A (en) Treatment of low pressure glaucoma and ischemic retinal degeneration with loxapine
Ohtsuka et al. Retinal projections to the accommodation-related area in the rostral superior colliculus of the cat
HK1016073A (en) Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
HK1142830A (en) Use of (2-imidazolin-2ylamino) quinoxalines for the manufacture of a medicament
MXPA97010480A (en) Method of use of (2-imidazolin-2-ilamino) quinoxalines to treat opt nerve injury

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Applicant after: Allergan Sales, INC.

Applicant before: A Legen

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: ALLERGAN TO: ALLERGAN SALES, INC.

ASS Succession or assignment of patent right

Owner name: ALLERGAN INC.

Free format text: FORMER OWNER: ALLERGAN SALES, INC.

Effective date: 20031218

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20031218

Address after: texas

Applicant after: Allergan

Address before: texas

Applicant before: Allergan Sales, INC.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 19981028

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1016073

Country of ref document: HK